You are here:

edoxaban (Lixiana)

Advice

following a full submission

edoxaban (Lixiana®) is accepted for use within NHS Scotland.

Indication under review: for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

One phase III study showed non-inferiority of edoxaban versus a vitamin K antagonist for the prevention of stroke and systemic embolism in adult patients with NVAF and a CHADS2 score of ≥2. It was also associated with a significant reduction in risk of major bleeding.

Drug Details

Drug Name: edoxaban (Lixiana)
SMC Drug ID: 1095/15
Manufacturer: Daiichi Sankyo UK Ltd
Indication: For prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 November 2015

Back